2018 OPPS final rule: CMS to cut 340B drug program payments by 22.5%
Despite opposition from many stakeholders, a bipartisan contingent of Congress and CMS’ own advisory panel, the agency is moving forward with its plan to drastically cut payments for drugs acquired through the 340B drug discount program, according to the 2018 OPPS final rule, released Nov. 1.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.